The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can ...

AS GLP-1 AGONISTS soar in popularity—about 12 percent of the U.S. population has tried one, most often Ozempic or Wegovy ...

Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...

2024 was another banner year for GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their developers with both rich remuneration and ...

Glucagon-like peptide 1 receptor agonists (GLP-1RA) are transforming the treatment of obesity and type 2 diabetes. As an approach to optimize efficacy and minimize side effects, co-agonists ...

The Big Pharma already has efinopegdutide, a dual GLP-1/glucagon receptor co-agonist that Merck touted last year as beating Novo Nordisk's blockbuster GLP-1 drug Ozempic in a phase 2 trial in the ...

Glucagon-like peptide-1 (GLP-1) receptor agonists have quickly become some of the most ubiquitous drugs in the United States. Though they were originally indicated to treat diabetes, and to assist ...